Taelor J. Ekstrom
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Taelor J. Ekstrom has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Amanda Zucker
Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University (OHSU), Portland, OR, 97201
2 shared publications - Melissa Hirose Wong
Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University (OHSU), Portland, OR, 97201
2 shared publications Abdenour Soufi
The University of Edinburgh, Centre for Regenerative Medicine, Institute of Regeneration and Repair, Institute of Stem Cell Research, Edinburgh, UK
1 shared publication- Abigail Moore
Department of Cell, Developmental and Cancer Biology, OHSU, Portland, OR, USA
1 shared publication - Adel Kardosh
Knight Cancer Institute, Oregon Health and Science University, Portland, OR
1 shared publication Amani Alshaikh
The University of Edinburgh, Centre for Regenerative Medicine, Institute of Regeneration and Repair, Institute of Stem Cell Research, Edinburgh, UK
1 shared publication
Latest Publications
- Open Access
Cyclic immunofluorescence platform using photocleavable linkers for direct antibody labeling enables cancer phenotyping
Advances in spatial proteomics through the development of multiplexed immunostaining platforms have facilitated analyses with increasing cellular and molecular granularity. However, currently available approaches are limited by harsh conditions for signal removal, restricting the number of antigens that can be probed in a single specimen without significant alterations to sample quality and structure. Here we present an approach for direct labeling of primary antibodies with fluorophores using a photocleavable linker (PCL) with a polyethylene glycol spacer (PEG) to enable cyclic immunofluorescence (cyCIF) with gentle signal removal conditions. Our innovative approach uses directly labeled primary antibodies to enhance staining specificity and cyclic immunostaining efficiency, while minimizing nonspecific background signal. Additionally, through integration of the PCL, this approach facilitates gentle cleavage of antibody conjugated fluorophore, preserving sample integrity over multiple rounds of staining. Direct PEG-PCL antibody labeling will promote greater multiplexing by minimizing specimen damage and allow for quantitative analyses of cyCIF spatial data. We demonstrate that cyCIF with PEG-PCL conjugated antibodies can be applied across a variety of cancer subtypes to identify and characterize rare neoplastic cell populations in both tumor tissue and fragile peripheral blood specimens.
Open AccessCyclic immunofluorescence platform using photocleavable linkers for direct antibody labeling enables cancer phenotyping
Advances in spatial proteomics through the development of multiplexed immunostaining platforms have facilitated analyses with increasing cellular and molecular granularity. However, currently available approaches are limited by harsh conditions for signal removal, restricting the number of antigens that can be probed in a single specimen without significant alterations to sample quality and structure. Here we present an approach for direct labeling of primary antibodies with fluorophores using a photocleavable linker (PCL) with a polyethylene glycol spacer (PEG) to enable cyclic immunofluorescence (cyCIF) with gentle signal removal conditions. Our innovative approach uses directly labeled primary antibodies to enhance staining specificity and cyclic immunostaining efficiency, while minimizing nonspecific background signal. Additionally, through integration of the PCL, this approach facilitates gentle cleavage of antibody conjugated fluorophore, preserving sample integrity over multiple rounds of staining. Direct PEG-PCL antibody labeling will promote greater multiplexing by minimizing specimen damage and allow for quantitative analyses of cyCIF spatial data. We demonstrate that cyCIF with PEG-PCL conjugated antibodies can be applied across a variety of cancer subtypes to identify and characterize rare neoplastic cell populations in both tumor tissue and fragile peripheral blood specimens.
- 22 May 2026
- Published by Springer Nature
- Vol. 1509, 369-401
Implications of Heterotypic Cell Fusion in Cancer
The interplay between discrete neoplastic cells and cells within the tumor microenvironment represents a critical component of cancer evolution that ultimately impacts patient outcomes. A newly identified neoplastic cell that is a product of cell fusion between neoplastic and immune cells has emerged as a key player in metastatic spread. Indeed, these hybrid cells are detected across the metastatic cascade: within the primary tumor, disseminated into the peripheral blood, and in metastatic sites. While multiple mechanisms of hybrid cells generation have been posited, cell fusion has the most rigorous prior study. Most commonly between tumor cells and macrophages, fusion progeny are identified by the co-expression of parental cell type features (e.g., epithelial proteins and immune cell antigens). After fusion, they become reprogrammed to be distinct from other neoplastic cells and demonstrate properties that enhance their ability to successfully travel through the metastatic cascade. As such, cell fusion hybrids have more recently gained traction as a means of tumorigenesis, metastatic spread, and treatment resistance. Importantly, investigators have demonstrated clinical utility for disseminated tumor-immune hybrids, called circulating hybrid cells (CHCs) in peripheral blood, for early detection, metastatic risk stratification, treatment resistance, and disease progression. Herein, we review the study of tumor hybrid cells as a new frontier of cancer biology and as a developing biomarker to enhance metrics for cancer patient care and survival.
- 22 May 2026
- Published by Springer Nature
- Vol. 1509, 369-401
Implications of Heterotypic Cell Fusion in Cancer
The interplay between discrete neoplastic cells and cells within the tumor microenvironment represents a critical component of cancer evolution that ultimately impacts patient outcomes. A newly identified neoplastic cell that is a product of cell fusion between neoplastic and immune cells has emerged as a key player in metastatic spread. Indeed, these hybrid cells are detected across the metastatic cascade: within the primary tumor, disseminated into the peripheral blood, and in metastatic sites. While multiple mechanisms of hybrid cells generation have been posited, cell fusion has the most rigorous prior study. Most commonly between tumor cells and macrophages, fusion progeny are identified by the co-expression of parental cell type features (e.g., epithelial proteins and immune cell antigens). After fusion, they become reprogrammed to be distinct from other neoplastic cells and demonstrate properties that enhance their ability to successfully travel through the metastatic cascade. As such, cell fusion hybrids have more recently gained traction as a means of tumorigenesis, metastatic spread, and treatment resistance. Importantly, investigators have demonstrated clinical utility for disseminated tumor-immune hybrids, called circulating hybrid cells (CHCs) in peripheral blood, for early detection, metastatic risk stratification, treatment resistance, and disease progression. Herein, we review the study of tumor hybrid cells as a new frontier of cancer biology and as a developing biomarker to enhance metrics for cancer patient care and survival.
- Open Access
Sendai virus is robust and consistent in delivering genes into human pancreatic cancer cells